The present invention represents a general platform for the delivery of protein-based substances on the surface of lactobacteria to the gastrointestinal tract. The production of such lactic acid bacteria is more cost effective compared to monoclonal antibodies, typically used to reduce TNFα in IBD patients.

Details about the Technology offer (click)